Chemical Business Newsbase articles from September 2010

Chemical Business Newsbase archives from September 2010

Hind Copper gets prospecting licence in Rajasthan.
September 30, 2010... The Rajasthan Government has granted prospecting lease to the public sector firm Hindustan Copper Ltd for a copper deposit at Baniwali KiDhani in Rajasthan. The approval was given following the approval from the Union Ministry of Mines. The...

Omega Pharma keen to grow in India via brand acquisition.
September 30, 2010... The Belgium-based over-the-counter (OTC) healthcare products maker Omega Pharmaceuticals plans to acquire one or two brands in India, where the market for OTC healthcare products is about Rup 4000 crores. The company operates in India through a...

Apollo Tyres plans big sales push in Europe: Supply constraints to ease when Chennai unit becomes fully operational.
September 30, 2010... Apollo Tyres, which launched passenger car radial tyres in Jun 2010, now plans to increase its share in the 200-300 M tyres/y European market. The Netherlands-based Apollo Vredestein BV plans to have its ultra-high performance Vredestein tyres...

ITC launches anti-hairfall shampoo.
September 30, 2010... ITC has introduced an anti-hairfall shampoo and conditioner under the Fiama Di Wills brand in Tamil Nadu priced at Rup 115/200 ml and Rup 50/100 ml packs. The conditioner is priced at Rup 60/90 ml and Rup 40/50 ml.

Bausch & Lomb eyes pharma, surgical biz.
September 30, 2010... Contact lens major Bausch & Lomb plans to foray into pharmaceuticals segment by retailing medicines for various eye diseases besides introducing therapeutic disposable contact lenses in India. The company has 55% market share in the Rup 130...

Circassia Ltd initiates Phase II trials of novel Grass and Ragweed allergy therapies and advances Phase III plans for Cat allergy T-Cell vaccine.
September 30, 2010... Circassia Ltd further advanced the clinical development of three of its leading T-cell allergy vaccines. In recent weeks, Circassia has initiated phase II clinical testing of its grass allergy therapy, begun the final stage of phase II testing...

Ablynx initiates Phase II clinical trial for TTP.
September 30, 2010... Ablynx has opened recruitment in its first clinical trial centre for an open-label, randomised Phase II study for patients with acquired thrombotic thrombocytopenic purpura (TTP). This Phase II study will be conducted in Europe and North America...

GW Pharmaceuticals starts Phase IIa study programme evaluating new cannabinoid medicines in Type 2 diabetes.(Report)
September 30, 2010... GW Pharmaceuticals plc (GW) has commenced the first of a programme of Phase IIa exploratory clinical trials exploring GW's cannabinoids as potential treatments in the field of Type 2 diabetes and metabolic syndrome. This study programme follows...

Prana Biotechnology selects lead PD drug candidate for development.
September 30, 2010... Prana Biotechnology (Prana) has selected a novel lead drug candidate to be developed as a disease modifying treatment for Parkinson's Disease (PD), PBT434. Accordingly, because PBT434 can: prevent the ongoing loss of substantia nigra cells,...

Premier Research contributed to the 13th World Congress on Pain.
September 30, 2010... Premier Research Group Ltd, an international CRO with unrivalled analgesia research expertise, recently contributed to the 13th World Congress on Pain. Dr Stephen Daniels, Executive Medical Director, co-authored six posters presented at the...

Kane Biotech Inc's DispersinB wound spray passes quality control and sterility tests.
September 30, 2010... Kane Biotech Inc announced that its DispersinB topical wound spray has passed all required quality control (QC) tests, including the sterility test, after a 12.5-week accelerated shelf-life study at 25 degrees C and 60 RH (Relative Humidity),...

Rosetta Genomics Ltd announces poster presentations at the American Association for Cancer Research's Molecular Diagnostics in Cancer Therapeutics Development Conference.
September 30, 2010... Rosetta Genomics Ltd announced that posters highlighting two of the company's second generation microRNA-based diagnostic assays were presented by the company's clinical laboratory director, Dr Tina B Edmonston, at the American Association for...

Stellar Biotechnologies Inc receives $288,000 payment from Neovacs SA.
September 30, 2010... Stellar Biotechnologies Inc received payment of $288,000 for a filled order of Stellar KLH/SUBUNIT from French biotechnology and active immunotherapy technology-platform company, Neovacs SA, for its Phase IIa human trials with its KLH-based...

Avid Bioservices Inc secures biomanufacturing contract with Affitech AS.
September 30, 2010... Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals Inc (Peregrine), has secured a biomanufacturing contract to supply clinical material over 2011 to Affitech A/S, the antibody medicines company. The initial contract for committed...

Peregrine Pharmaceuticals Inc and Affitech AS to amend licence agreements to expedite development of novel fully human anti-VEGF antibody AT001/R84.
September 30, 2010... Peregrine Pharmaceuticals Inc (Peregrine) and Affitech A/S, the antibody medicines company, have agreed to amend certain terms of their worldwide licence agreements for Brazil, Russia and other countries of the Commonwealth of Independent States...

Inovio Pharmaceuticals (formerly known as Inovio Biomedical Corp) SynCon universal influenza DNA vaccine technology recognized with National Institutes of Health (NIH) director's transformative research award.
September 30, 2010... Inovio Pharmaceuticals Inc (Inovio) announced that Inovio Pharmaceuticals and the University of Pennsylvania have received a grant of $3.1 M from the National Institutes of Health (NIH) Director's Office to further fund Inovio's universal SynCon...

Bavarian Nordic realigns for expansion; primary business divided into two divisions, executive management consolidated.
September 30, 2010... Bavarian Nordic A/S announced the reorganization of the company's primary business areas into two divisions; Cancer Vaccines and Infectious Diseases each led by its own Division President reporting to the President & CEO of the company....

SciClone Pharmaceuticals Inc identifies unique genetic markers associated with patient response to SCV-07 treatment in oral mucositis.
September 30, 2010... SciClone Pharmaceuticals Inc (SciClone) announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the company's Phase IIa proof of concept study of SCV-07 for the prevention of...

SOLON to develop and build breakthrough 18 MW solar power plant for Arizona Public Service.
September 30, 2010... Tucson-based SOLON Corp, one of the largest crystalline silicon solar module manufacturers and provider of turnkey solar power plants in the US announced a contract with Arizona Public Service (APS) to develop, design and construct an 18 MW...

Glen Rose Petroleum Corp announces acquisition of Adamson Ranch.
September 30, 2010... Glen Rose Petroleum Corp (GRPC), a developer of on-shore US oil and gas assets, has acquired the 5400 acre Adamson Ranch in Edwards County, TX, which is contiguous to the company's Wardlaw leasehold property, bringing its total acreage to...

Intertek expands environmental testing in Mexico.
September 30, 2010... Intertek, a leading provider of quality and safety solutions serving a wide range of industries around the world announced the opening of a new environmental laboratory in Villahermosa. The primary function of the new laboratory will further...

Technip awarded two hydrogen plant contracts in the US.
September 30, 2010... Technip has been awarded two lump sum contracts by Valero Refining Co and Diamond Shamrock Refining Co (both part of the Valero group) for two hydrogen plants at their refineries in Memphis, TN and McKee, TX. The two 30 M standard cu ft/day...

VIRxSYS Corp demonstrates 'functional cure' and survival benefit for the simian model of HIV in pre-clinical vaccine study.
September 30, 2010... VIRxSYS Corp, a privately held company developing vaccines and RNA therapies for serious human diseases presented results from a study of VRX1116, a simian analogue for an investigational, lentiviral-based vaccine for HIV VRX1273, at the AIDS...

United EcoEnergy Corp announces name change to United Health Products Inc.
September 30, 2010... United EcoEnergy Corp announces that the company has changed its name to United Health Products Inc effective 30 Sep 2010. The name change to United Health Products Inc will be reflected in SEC filings and all future corporate communications...

PPD opens office in Novosibirsk, Russia.
September 30, 2010... PPD Inc has opened an office in Novosibirsk, Russia, building on the growth of its Phase II-IV clinical development services in Eastern Europe. PPD will provide clinical monitoring services in key therapeutic areas from this location. The new...

Merck to appeal verdict in Massachusetts medicaid case.
September 30, 2010... Merck & Co Inc will vigorously appeal a Massachusetts federal court jury verdict concerning allegations that a former subsidiary of Schering-Plough Corp, Warrick Pharmaceuticals (Warrick), caused the Commonwealth of Massachusetts to overpay...

Mars defence of flavanol patent portfolio successful.
September 30, 2010... Mars Inc has successfully defended its cocoa flavanol patent portfolio in a recent lawsuit against flavanol extract supplier Naturex, maker of the CocoActiv product, and against flavanol supplement manufacturers Nutraceutical Corp, seller of...

Benitec: Approval of US Graham '099 patent in RNA interference post re-examination hearing.
September 30, 2010... Benitec Ltd announced the US Patent and Trademark Office's (USPTO) Board of Patent Appeals and Interferences decision (the Decision) reversing all previous rejections in the US 6,573,099 (the '099 Graham patent) appeal. The rejection of all...

Teva provides update on status of Neutroval (G-CSF) Biologics License Application submitted to the US Food and Drug Administration.
September 30, 2010... Teva Pharmaceutical Industries Ltd (Teva) announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval (granulocyte colony-stimulating factor) for the...

Juvaris BioTherapeutics announces publication of pre-clinical anti-leukaemia effects of JVRS-100 immunotherapy.
September 30, 2010... Juvaris BioTherapeutics Inc (Juvaris) announced that results from pre-clinical studies using its lead compound, JVRS-100, as an immunotherapy to treat acute myelogenous leukaemia (AML) were published in the Sep 2010 edition of the journal Cancer...

Meridian Bioscience receives Canadian license for illumigene C difficile.
September 30, 2010... Meridian Bioscience Inc has received an approved medical device license from Health Canada for its new molecular amplification assay, illumigene C difficile. The illumigene molecular amplification assay detects the presence of the toxin...

Oragenics Inc announces distribution agreement to bring Teddy's Pride oral care probiotics for cats and dogs to Taiwan.
September 30, 2010... Florida-based biopharmaceutical company Oragenics Inc has announced that its oral care probiotic for cats and dogs, Teddy's Pride will be available in Taiwan through a distribution agreement with The Best Supplies Ltd. Teddy's Pride was very...

Avila initiates Phase I clinical study of AVL-292, a targeted covalent drug and novel potential treatment for B cell cancers and autoimmune diseases.
September 30, 2010... Avila Therapeutics Inc (Avila) has initiated a Phase I clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the...

PolyMedix receives Phase II NIH grant to develop a novel antimicrobial defensin mimetic for oral candidiasis.
September 30, 2010... PolyMedix Inc has received a Phase II grant in the amount of $986,000 from the NIH to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through...

AVEO Pharmaceuticals regains worldwide rights to develop and commercialize anti-HGF antibody candidate AV-299.
September 30, 2010... AVEO Pharmaceuticals Inc has regained worldwide rights from Merck (through its subsidiary, Schering Corp) to develop and commercialize AV-299 (SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate. AV-299 is a potent,...

FDA Grants Type B meeting to be held 8 Nov 2010 to discuss Phase III protocols for Androxal.
September 30, 2010... Repros Therapeutics Inc has been granted a Type B meeting to be held on 8 Nov 2010 with the Division of Reproductive and Urologic Products to review the company's Phase III pivotal efficacy protocols for Androxal in the treatment of secondary...

Teva and OncoGenex announce initiation of second Phase III trial of Custirsen in men with metastatic prostate cancer.
September 30, 2010... Teva Pharmaceuticals Industries Ltd and OncoGenex Pharmaceuticals Inc announced the initiation of SYNERGY, a global Phase III trial evaluating custirsen as first line therapy for the treatment of castrate-resistant prostate cancer. The SYNERGY...

Dyax and CMIC Co Ltd announce partnership to develop and commercialize subcutaneous DX-88 (ecallantide) for hereditary angioedema and other indications in Japan.
September 30, 2010... Dyax Corp and CMIC Co Ltd announced an agreement to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE) and other angioedema indications in Japan. DX-88 has been approved by the USFDA and...

WD-40 Co increases regular quarterly dividend by 8%.
September 30, 2010... WD-40 Co announced that its board of directors declared on 1 Oct 2010 an increase in the regular quarterly dividend to $0.27/share, payable 29 Oct 2010 to stockholders of record on 14 Oct 2010. WD-40 Co, with headquarters in San Diego, is a...

NuCO2 announces strategic alliance with Praxair.
September 30, 2010... NuCO2, the largest supplier in the US of beverage carbonation services for the restaurant and hospitality industry, which is owned by Los Angeles-based private equity firm Aurora Capital Group, announced that it has formed a strategic alliance...

Albemarle to increase price of elemental bromine and hydrobromic acid.
September 30, 2010... Albemarle Corp, a leading speciality chemicals maker, announced that it will increase its global prices for elemental bromine by $500/tonnes and all grades of hydrobromic acid by $250/tonnes. The price increases will take effect 1 Nov 2010, or...

Reportlinker adds survey of pesticide industry in China.
September 30, 2010... Reportlinker.com announces that a new market research report is available in its catalogue: Survey of Pesticide Industry in China. China now plays an important role in pesticide production in the world. It is the biggest pesticide producer...

Savient Pharmaceuticals announces dismissal of class action lawsuit.
September 30, 2010... Savient Pharmaceuticals announced that the United States District Court for the Southern District of NY has dismissed the Class Action originally filed on 25 Nov 2008, and captioned Richard Sagall versus Savient Pharmaceuticals Inc against the...

FDA orders halt to marketing of unapproved single-ingredient oral colchicine.
September 30, 2010... The US Food and Drug Administration took action against companies that manufacture, distribute, and/or market unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat acute gout...

European Food Safety Authority (EFSA) reconfirms safe use of bisphenol A in food contact products.
September 30, 2010... The American Chemistry Council (ACC) issued the following statement in response to a European Food Safety Authority (EFSA) announcement about consumers and the safety of bisphenol A (BPA). For the third time since 2007, and as a result of a...

Neupro (rotigotine) provided clinically relevant improvements in health-related quality of life for people with Parkinson's disease.
September 30, 2010... People with Parkinson's disease who used once-daily Neupro (rotigotine) in the RECOVER trial achieved improvements in quality of life, in addition to previously reported beneficial effects on motor and non-motor symptoms. Data presented at the...

A brief explanation of dopamine-beta-hydroxylase (DBH)- SymPath: in vitro diagnostic test to distinguish anxious disorders from depressive disorders.
September 30, 2010... Neuro-Biotech Corp in acquiring licenses to commercialize 12 neuro-biomarkers has first focused on SymPath and is now ready to give the opportunity to shed some light about this neuro-biomarker of the sympathetic nervous system (SNS). Here is a...

Surveyed European oncologists assign greater patient share to Johnson & Johnson's abiraterone compared with other emerging therapies in asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.
September 30, 2010... Decision Resources finds that, according to surveyed European oncologists, Johnson & Johnson's abiraterone will capture greater patient share than Dendreon's Provenge, AstraZeneca's zibotentan or Bristol-Myers Squibb's ipilimumab in...

Max Neeman International initiates large Phase IV trial on Type II diabetes with 25,000 subjects across 1200 sites.
September 30, 2010... A global pharmaceutical company has initiated a prospective trial to evaluate the impact of insulin guidelines developed by the Indian National Consensus group in collaboration with Max Neeman, a leading India-based Contract Research...

New study reveals Collagenase Santyl Ointment more effective than hydrogel dressing for pressure ulcer debridement.
September 30, 2010... Healthpoint announced that the results of a new study conducted by Catherine T Milne APRN, MSN, CWOCN, BC-ANP, will be presented on 30 Sep 2010 at the Healthpoint booth during the 25th Annual Clinical Symposium on Advances in Skin & Wound...

Data Monitoring Committee unanimously recommends continuation of Celsion's Phase III ThermoDox HEAT study to treat primary liver cancer.
September 30, 2010... Celsion Corp announced that after reviewing data from 401 patients enrolled in its pivotal Phase III ThermoDox clinical study (the HEAT study) for primary liver cancer, the Data Monitoring Committee (DMC) has unanimously recommended that the...

Solutia introduces new Saflex S series advanced solar interlayer for global automotive market.
September 30, 2010... On 30 Sep 2010, Solutia Inc introduced the company's new Saflex S series advanced solar absorbing interlayer for the global automotive glazing market. The product is being featured at the company's booth at Glasstec 2010, held in Dusseldorf,...

Announcement: free aid for skin conditions.
September 30, 2010... Substantially relieving skin dryness and eczema symptoms has been the extremely positive experiences of NewFresh Water Systems (NewFresh Water) customers, based on feedback and comments from usages of their products. The InjectaFLO line was...

Repligen announces completion of patient enrolment in Phase IIb clinical trial of RG2417 for bipolar depression.(Clinical report)
September 30, 2010... Repligen Corp has reported that it has completed enrolment of patients in its Phase IIb clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This study is a double-blind, placebo-controlled trial...

Positive top-line results from Phase III GETGOAL clinical trial using once-daily lixisenatide in combination with basal insulin.
September 30, 2010... Zealand Pharma A/S has noted that its partner, sanofi-aventis, has announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered...

Teva and Oncogenex announce initiation of second Phase III trial of custirsen in men with metastatic prostate cancer.
September 30, 2010... Teva Pharmaceuticals Industries Ltd (Teva) and OncoGenex Pharmaceuticals Inc (OncoGenex) have announced the initiation of Synergy, a global Phase III trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the...

Covance and Sanofi-Aventis sign definitive agreements for ten-year strategic R&D alliance.
September 30, 2010... Covance Inc has announced the signing of definitive agreements with sanofi-aventis for Covance to become sanofi-aventis' R&D partner. Through 2020, Covance expects to provide drug development services to sanofi-aventis, with estimated...

China XD Plastics Co Ltd signs delivery agreement for 2000 tonnes/y of modified plastics for use in electric vehicles.
September 30, 2010... China XD Plastics Co Ltd (China XD) has announced that it has signed a delivery agreement for 2000 tonnes/y of environmentally friendly and high-value added modified plastics designed for use in electric vehicles. The first batch of the product...

Circassia initiates Phase II trials of novel grass and ragweed allergy therapies and advances Phase III plans for cat allergy T-cell vaccine.
September 30, 2010... Circassia Ltd has further advanced the clinical development of three of its leading T-cell allergy vaccines. In recent weeks, Circassia has initiated Phase II clinical testing of its grass allergy (hayfever) therapy, begun the final stage of...

Cypher sirolimus drug-eluting stent remains unsurpassed in terms of clinical safety and efficacy.
September 30, 2010... Investigators reported results of SORT-OUT IV, comparing Cordis Corp's Cypher Sirolimus-eluting Coronary Stent and Abbott's Xience V Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months. These...

ThromboGenics signs deal with MSD for long-term commercial supply of microplasmin.
September 30, 2010... ThromboGenics NV has signed a 10-year supply agreement with MSD Biologics (UK) Ltd (MSD), part of the Merck BioManufacturing Network, for the production of microplasmin. ThromboGenics anticipates that this deal will meet its long-term commercial...

Canpotex enters into long-term sales agreement with Indonesia.
September 30, 2010... Canpotex announces the signing of a five-year Memorandum of Understanding (MOU) with an Indonesian buying consortium for volumes totalling 3.75 M tonnes of potash. On 20 Sep 2010, a 13-member Indonesian delegation led by Wilmar Trading Pte Ltd...

Court approves Tronox's Disclosure Statement.
September 30, 2010... Tronox Inc, on behalf of itself and its affiliated debtors and debtors in possession, announced that on 30 Sep 2010, the US Bankruptcy Court for the Southern District of New York (the Bankruptcy Court) approved the Disclosure Statement Regarding...

Reportlinker adds Survey of Titanium Dioxide in China-the Fifth Edition.
September 30, 2010... Reportlinker.com announces that a new market research report is available in its catalogue: Survey of Titanium Dioxide in China-the Fifth Edition. At present, the production capacity of titanium dioxide in China accounts to 30% of the world...

Indian courts close Vedanta copper smelter.
September 30, 2010... Vedanta Resources, the Indian mining company that in recent years has been widely condemned for its human rights and environmental record, suffered another blow yesterday when the high court in Madras ordered a subsidiary of the group to close...

BP crack downs on safety in major shake-up. Head of exploration division at time of Deepwater Horizon explosion to leave.
September 30, 2010... BP tried to turn the tide against its battered reputation yesterday, creating a new safety and risk division and reshuffling its top team of managers just two days before Bob Dudley takes over as the energy giant's new chief executive. Andy...

Dudley prepares for stage two of the great BP clean-up.
September 30, 2010... Robert Dudley is clearly desperate to make an early splash as he replaces Tony Hayward in the chief executive's office. His announcement of a management shake-up is the beginning of a campaign to put the Gulf of Mexico catastrophe behind BP. Out...

Malaria vaccine for Africa closer than ever, scientists say.
September 30, 2010... Scientists are closer than ever to rolling out the first malaria vaccine, which could be available in Africa by 2015, a co-inventor of the shot against the killer disease said. Advanced trials of the RTS,S vaccine against falciparum malaria, the...

Trio-Tech 2009-2010 revenue increases 85% to $37 M.(Financial report)
September 30, 2010... Trio-Tech International (Trio-Tech) announced that revenue for 4Q ended Jun 2010 tripled to $12.874 M ($4.328 M for 4Q ended Jun 2009). Net income for 4Q 2009-2010 was $323,000 (loss of $683,000 for 4Q 2008-2009). Revenue from product sales...

Jiangbo Pharmaceuticals announces 4Q and financial Year 2009-2010 Results.
September 30, 2010... Jiangbo Pharmaceuticals Inc (Jiangbo) announced financial results for its 4Q and financial year ended 30 Jun 2010. Company's revenues decreased year-over-year to $29,308,512 in the 4Q ended 30 Jun 2010 (-5.9% from $31,152,620 in the 4Q ended 30...

Proteome Sciences PLC: Results for 1H ended Jun 2010 highlights.
September 30, 2010... Proteome Sciences plc announced its interim results for 1H ended Jun 2010. The unaudited financial results for 1H 2010 show a loss before tax of GBP 2.264 M (loss of GBP 2.485 M in 1H 2009). This reduction in the loss before taxation reflects...

Genfit Corp: Results for 1H 2010.
September 30, 2010... Genfit announces its financial results for 1H ended Jun 2010. The total operating revenues for 1H 2010 amounted to EUR 4.08 M (EUR 5.62 M in 1H 2009). Industrial revenues amounted to EUR 2.06 M for 1H 2010, and were largely made up of the...

Dutch chemical industry recovers in 1H 2010 relative to 1H 2009.
September 30, 2010... In 1H 2010 the Dutch chemical industry reported a production growth of 14.7% relative to 1H 2009, with turnover increasing by 35.8%. The main recovery occurred in 2H 2009 and decreased somewhat in 1H 2010; a further slackening in recovery is...

Upturn for European chemical industry in 1H 2010.
September 30, 2010... According to Cefic the European chemical industry recorded an increase in production, sales, trade surplus, price rises, and confidence in Jul 2010 compared with in Jul 2009. Production was 6.5% higher in Jul 2010 than in Jul 2009 and output in...

HB Fuller announces $100 M Share repurchase program; declares regular quarterly dividend.
September 30, 2010... On 30 Sep 2010, HB Fuller Co announced that its Board of Directors has authorized a share repurchase program of up to $100 M of the company's outstanding common shares and declared a regular quarterly cash dividend of $0.07 per share of common...

Ube moves to strengthen caprolactam and nylon production in Thailand.
September 30, 2010... On 30 Sep 2010, Ube Industries Ltd announced that it is strengthening its production capacity for caprolactam and nylon in Thailand, to meet rising demand in the Asia region including China. The production capacity increases will be implemented...

Ube Industries to revise price of diol products.
September 30, 2010... On 30 Sep 2010, Ube Industries Ltd announced that it will implement a price increase for diol products (1,6-hexanediol and 1,5-pentanediol) in Japan and other parts of Asia effective for shipments on or after 1 Oct 2010. This price revision...

UPM EcoMail - a new Kraft MG envelope with strong environmental credentials.
September 30, 2010... UPM has launched a new product called UPM EcoMail as part of its MG Kraft envelope paper range. It is an economical and ecological paper for fast running envelope and pocket machines. It is based on OCC recycled fibre. The fibre is collected...

Dow introduces world's first PVC/Halogen-Free solution to meet key global standards.
September 30, 2010... Electronics OEMs looking for PVC alternatives to make flexible cords safer and more environmentally sustainable now have options thanks to the introduction of DOW SUSTAIN halogen-free compounds from The Dow Chemical Co. Developed by Dow Wire...

Dow launches clean and efficient bathtub reinforcement technology.
September 30, 2010... Dow Formulated Systems announces the launch of the DURELAST Bathtub Reinforcing System. DURELAST technology offers bathtub manufacturers cleaner and more efficient production. The new bathtub system will officially be launched at the K2010...

Mitsubishi building PET film plant in China.
September 30, 2010... Tokyo-based Mitsubishi Plastics Inc will set up a PET film facility in China, in response to increasing demand in the flat panel display market for television screens and computer monitors. The Yen 24 bn ($288 M) plant will be built in Suzhou,...

Food distributor to use biodegradable packaging.
September 30, 2010... Food distributor Richmond Wholesale has forged a deal with EcoLogic LLC of Oakbrook, IL, USA as part of efforts to advance its sustainable packaging initiative. The Richmond-based firm intends to use EcoLogic's EcoPure additive in all the...

Songwon to announce projects at K 2010.
September 30, 2010... South Korean plastics additives producer Songwon Industrial Co Ltd will disclose details of an antioxidant capacity expansion and a jv with a Chinese thioester manufacturer at the K 2010 trade show in Germany. Songwon is said to be the second...

Cardia enters Malaysia packaging market.
September 30, 2010... Cardia Bioplastics Ltd is venturing into the Malaysian plastic packaging market via a venture with RNZ Green Bio. The new Malaysian company Cardia Bioplastics Malaysia Manufacturing was formed to make finished bioplastic products.